Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia

Clinical Therapeutics

Volumn 30, Issue 4, 2008, Pages 717-733

  Merchant, Sanjay ^a   Gast, Chris ^b   Nathwani, Dilip ^c   Lee, Michael ^a   Quintana, Alvaro ^a   Ketter, Nzeera ^a   Friedland, Ian ^a   Ingham, Michael ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Axio Research Corporation   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

doripenem; economic; resource utilization; ventilator associated pneumonia

Indexed keywords

AMIKACIN; CARBAPENEM; DORIPENEM; IMIPENEM; VANCOMYCIN;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MALE; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; STATISTICAL SIGNIFICANCE; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; COSTS AND COST ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HOSPITAL COSTS; HUMANS; IMIPENEM; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMONIA, VENTILATOR-ASSOCIATED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 43549084118     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.04.001     Document Type: Article

References (30)